About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
A controversial bill to change the classification of the opioid hydrocodone from Schedule III to Schedule II might help decrease the incidence of drug abuse through stricter regulation of Schedule II products, or, as some groups claim, it might hinder access for patients with legitimate prescriptions.
Jennifer A. Gershman, PharmD, CPh; and Andrea D. Fass, PharmD
Mortality rates for cardiovascular disease are higher in women than in men, but studies of women have been conducted less frequently. Current pharmacological and nonpharmacological treatment options for women with stable angina are reviewed.
Raheleh Sarbaziha, MD; Tara Sedlak, MD; Chrisandra Shufelt, MD, MS; Puja K. Mehta, MD; and C. Noel Bairey Merz, MD
Controversies in Practice
To Compound or Not to Compound—That Is the Question
Preterm births have increased by 27% over the last decade in the U.S. The main ingredient in Makena, 17P, is less expensive at compounding pharmacies, but this method is not FDA-approved. The authors discuss the quality, safety, and use of Makena and compounded 17P; the potential for liability; cost considerations; and recommended restrictions for the product’s use.
Yesha Patel, PharmD; and Martha M. Rumore, PharmD, JD
Continuing Education Credit
Chronic nonmalignant pain, which affects millions of people, is the most common reason patients seek medical care. Both current and potential opioid analgesics are discussed, along with new technologies used to prevent abuse.
Robin Moorman-Li, PharmD, BCACP; Carol A. Motycka, PharmD, BCACP; Lisa D. Inge, PharmD, BCPS, BCACP, AAHIVE; Jocelyn Myrand Congdon, PharmD; Susan Hobson, PharmD; and Brian Pokropski, PharmD
The physical design of an organization’s workspace can enhance or diminish patient safety.
Matthew Grissinger, RPh, FaScP
Drug companies may be required to report shortages sooner, but the FDA legislation still lacks power.
FDA approvals, drug indications, and updates
Tazarotene (Fabior Foam) for acne; estradiol valerate and estradiol valerate/dienogest (Natazia) for heavy menstrual bleeding; and taliglucerase alfa (Elelyso) for Gaucher’s disease
Marvin M. Goldenberg, PhD, RPh, MS
A Clinical Review
Fospropofol disodium (Lusedra) for anesthesia sedation
Ramy Boules, PharmD; Andrew Szkiladz, PharmD; and Anna Nogid, BS, PharmD, BCPS